Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Valuable Targets
6 min read
Progress and Challenges in Targeted Cancer Metabolic Drugs - IDH2 inhibitors
26 September 2023
IDH2, or isocitrate dehydrogenase 2, is an enzyme that plays a crucial role in cellular metabolism.
Drug Insights
4 min read
Decoding Chlortetracycline: A Comprehensive Study of its R&D Trends
26 September 2023
This article summarized the latest R&D progress of Chlortetracycline, the Mechanism of Action for Chlortetracycline, and the drug target R&D trends for Chlortetracycline.
Latest Hotspot
4 min read
LAPIX Therapeutics Inc. reports FDA has approved their IND application for LPX-TI641, designed to treat for Multiple Sclerosis
26 September 2023
LAPIX Therapeutics, Inc. announced U.S. FDA clearance of its IND application. The approval enables Phase 1 trials for its leader compound, LPX-TI641, aimed at treating multiple sclerosis.
Drug Insights
4 min read
Deep Scientific Insights on Ceritinib's R&D Progress, Mechanism of Action, and Drug Target
26 September 2023
This article summarized the latest R&D progress of Ceritinib, the Mechanism of Action for Ceritinib, and the drug target R&D trends for Ceritinib.
Bio Sequence
2 min read
Biosequence Assistant: Rapid Extraction and Localization of Sequence Information in Patents
26 September 2023
Experience the New Features of the Patsnap Bio Sequence Database in September
Drug Insights
4 min read
An In-depth Analysis of Celastrol's R&D Progress and Mechanism of Action on Drug Target
26 September 2023
This article summarized the latest R&D progress of Celastrol, the Mechanism of Action for Celastrol, and the drug target R&D trends for Celastrol.
Latest Hotspot
3 min read
Revolution Medicines initiates dosing in Phase 1/1b clinical study for RMC-9805, an orally administered, covalent, mutant-specific KRASG12D inhibitor
26 September 2023
Revolution Medicines, Inc. has initiated Phase 1/1b trials for RMC-9805, a covalent, oral KRAS G12D inhibitor for RAS-dependent cancers and the first patient already dosed targeting KRAS G12D mutation-driven cancers.
Drug Insights
4 min read
Istradefylline: Detailed Review of its Transformative R&D Success
25 September 2023
This article summarized the latest R&D progress of Istradefylline, the Mechanism of Action for Istradefylline, and the drug target R&D trends for Istradefylline.
Valuable Targets
5 min read
New approach to cancer treatment-MDM2 inhibitors
25 September 2023
MDM2 is a crucial protein found in the human body that plays a significant role in regulating cell growth and division.
Drug Insights
4 min read
ADO-Trastuzumab Emtansine Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
25 September 2023
This article summarized the latest R&D progress of ADO-Trastuzumab Emtansine, the Mechanism of Action for ADO-Trastuzumab Emtansine, and the drug target R&D trends for ADO-Trastuzumab Emtansine.
Latest Hotspot
3 min read
Cerevance doses first participant for CVN293 in the Phase 1 Clinical Trial, to potentially treat ALS and Alzheimer's Disease
25 September 2023
Cerevance announced the start of their Phase 1 trial, with the first participant dosed to evaluate the safety, tolerability, and pharmacokinetics of CVN293.
Drug Insights
4 min read
Unleashing the Power of Vadadustat: A Comprehensive Review on R&D Breakthroughs
25 September 2023
This article summarized the latest R&D progress of Vadadustat, the Mechanism of Action for Vadadustat, and the drug target R&D trends for Vadadustat.